Cytokinetics, Incorporated
CYTK
Rangering i aksjer
#2257
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aksjekurs
$64.25
Markedsverdi
$8.93B
Endring (1 dag)
2.56%
Endring (1 år)
8.26%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Kategori
Healthcare
Antall utestående aksjer for Cytokinetics, Incorporated (CYTK)
Antall utestående aksjer per June 2026: 132.09M
Ifølge Cytokinetics, Incorporated sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 132.09M. Ved slutten av December 2023 hadde selskapet 96.52M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Cytokinetics, Incorporated (CYTK) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 132.09M | 17.96% |
| 2024 | 111.98M | 16.01% |
| 2023 | 96.52M | 7.46% |
| 2022 | 89.83M | 16.83% |
| 2021 | 76.89M | 19.16% |
| 2020 | 64.52M | 12.07% |
| 2019 | 57.58M | 5.80% |
| 2018 | 54.42M | 10.15% |
| 2017 | 49.40M | 23.69% |
| 2016 | 39.94M | 3.32% |
| 2015 | 38.66M | 8.27% |
| 2014 | 35.71M | 30.92% |
| 2013 | 27.28M | 50.63% |
| 2012 | 18.11M | 53.45% |
| 2011 | 11.80M | 10.34% |
| 2010 | 10.69M | 11.81% |
| 2009 | 9.57M | 16.19% |
| 2008 | 8.23M | 3.79% |
| 2007 | 7.93M | 29.96% |
| 2006 | 6.10M | 28.12% |
| 2005 | 4.76M | 44.51% |
| 2004 | 3.30M | 935.01% |
| 2003 | 318.50K | 9.70% |
| 2002 | 290.33K | 22.69% |
| 2001 | 236.64K | 47.10% |
| 2000 | 160.87K | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 92.22% |
US
|
|
| 396.00M | 199.80% |
US
|
|
| 478.91M | 262.58% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.92% |
NL
|
